Publications

1. GVS advice nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19

   The National Health Care Institute has assessed whether nirmatrelvir/ritonavir (Paxlovid®) can be included in the Medicine ...

   Report | 27-10-2022

2. GVS advice on natalizumab SC (Tysabri®) for adult patients with highly active RRMS

   The National Health Care Institute has completed its assessment whether natalizumab SC (Tysabri®) can be included in the Medicine ...

   Report | 25-10-2022

3. Package advice on ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsing and refractory multiple myeloma (RRMM)

   The National Health Care Institute advises the Minister not to include ciltacabtagene autoleucel (Carvykti®) for the treatment of ...

   Report | 20-10-2022

4. GVS advice to include the relugolix in combination with oestradiol and norethisteronacetate (Ryeqo®) combination

   The National Health Care Institute has completed its assessment whether relugolix in combination with oestradiol and ...

   Report | 19-10-2022

5. Evaluation and reassessment of further conditions for fampridine (Fampyra®)

   The National Health Care Institute advises the Minister that the fampridine (Fampyra®) conditions be revised and that the annual ...

   Report | 17-10-2022

6. Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

   The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...

   Report | 27-09-2022

7. GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection

   The National Health Care Institute advises the Minister to include lenacapavir (Sunlenca®) on List 1B of the Medicine ...

   Report | 22-09-2022

8. Package advice on pegcetacoplan (Aspaveli®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)

   The National Health Care Insititute has completed its assessment whether pegcetacoplan (Aspaveli®) can be included in the basic ...

   Report | 16-09-2022

9. Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma

   The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...

   Report | 09-09-2022

10. Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer

    The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...

    Report | 29-07-2022